HistoSonics Raises Financing for Expansion of Edison Histotripsy System

October 29, 2025—HistoSonics, Inc., developer of the Edison histotripsy system and histotripsy therapy platform, announced the closing of $250 million in financing that will support the ongoing commercial expansion of the Edison system into new global markets, accelerate new clinical indications throughout the body, and strengthen operational capacity for the next phase of growth.

According to the company, the funding was led by its new ownership group and included additional investors Thiel Bio and Founders Fund, among others.

In August 2025, the company announced a $2.25 billion majority stake acquisition by a consortium of international technology and life science investors, including K5 Global, Bezos Expeditions, and Wellington Management, who all participated in the new round that positions HistoSonics to advance its strategic priorities as a privately held company.

HistoSonics received its first FDA de novo clearance in October 2023 and is developing a noninvasive therapy that uses histotripsy—therapeutic focused ultrasound energy—to liquefy and destroy tumors and tissue under real-time image guidance.

The company advised that it plans to expand beyond its initial focus on liver tumors to kidney, pancreas, and prostate indications, with the goal of establishing histotripsy as a treatment option across a wide range of clinical applications throughout the body, treating both benign and malignant conditions.